Margetuximab
- Generic Name
- Margetuximab
- Brand Names
- Margenza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1350624-75-7
- Unique Ingredient Identifier
- K911R84KEW
- Background
The HER2 oncoprotein, the product of the human ERBB2/mouse neu genes, is a member of the HER family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR). Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by ERBB2 overexpression, a higher grade, a more aggressive phenotype, and a worse pro...
- Indication
Margetuximab is an anti-HER2 monoclonal antibody indicated, in combination with chemotherapy, for the treatment of metastatic HER2-positive breast cancer in adult patients who have received two or more prior anti-HER2 regimens with at least one prior regimen for metastatic disease.
- Associated Conditions
- Metastatic Breast Cancer With HER2 Positive
- Associated Therapies
- -
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- MedSIR
- Registration Number
- NCT05227131
MARGetuximab Or Trastuzumab (MARGOT)
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 174
- Registration Number
- NCT04425018
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana-Farber Brigham Cancer Center - Foxborough, Foxboro, Massachusetts, United States
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 123
- Registration Number
- NCT04262804
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.